Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
NCT02157558Phase 1Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Jul 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telotristat ethyl in Carcinoid Syndrome (CS), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoint: Fexofenadine plasma concentration in combination with steady state telotristat etiprate at Day 10. Started Jul 2014; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT02157558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157558.